Brain natriuretic peptide increases urinary albumin and alpha‐1 microglobulin excretion in Type 1 diabetes mellitus

McKenna, Kenneth Z.; Smith, Diarmuid; Moore, KB; Glen, A.I.M.; Tormey, William; Thompson, CJ

doi:10.1046/j.0742-3071.2001.00569.x

Cited by 17 publications

(12 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yano et al have shown that the plasma BNP level was significantly associated with the degree of microalbuminuria in normotensive diabetic patients without any cardiac dysfunction [12]. McKenna et al have reported that intravenous infusion of BNP increased the urine excretion of albumin in patients with Type 1 diabetes [13]. These reports appear to suggest that BNP might be related to the presence of diabetic complications.…”

mentioning

confidence: 86%

“…Thus, it is likely that BNP may be useful as a potential biomarker for the severity of CHF in diabetic patients. In addition, several investigators, but not all, have recently shown that the plasma BNP level could be elevated in association with the presence of diabetic complications [12,13]. Indeed, diabetes mellitus has the possibility to induce sodium retention and volume expansion, eventually affecting the cardiac hormone systems.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Characterization of Plasma Brain Natriuretic Peptide Level in Patients with Type 2 Diabetes

et al. 2005

View full text Add to dashboard Cite

Abstract. This study investigates whether the plasma brain natriuretic peptide (BNP) level is increased by the clinical traits of diabetes, including its complications, and whether these levels are affected by the presence of other combined diseases such as hypertension, hyperlipidemia, and coronary heart disease (CHD) in patients with diabetes. In 223 patients with Type 2 diabetes, the mean value of plasma BNP reached 32.3 ± 4.1 pg/mL. The levels significantly increased with age, hypertension, and CHD but not with the duration of diabetes, HbA1c level, or hyperlipidemia. With regard to the type of therapy, the BNP levels were significantly lower in the combinations of both sulfonylurea and metformin and sulfonylurea and pioglitazone than those in insulin alone. In addition, the BNP levels in the group with diabetic complications, including retinopathy and nephropathy, and macroalbuminuria were significantly elevated in comparison with those without these complications and macroalbuminuria. Interestingly, however, no difference was observed between these groups after removal of the values in patients with CHD. These results have clarified that the plasma BNP levels in diabetic patients could increase only by the progression of macrovascular diseases, such as CHD, but not by the current diabetic control or diabetic microvascular complications.

show abstract

mentioning

confidence: 86%

Section: Discussionmentioning

confidence: 99%

Characterization of Plasma Brain Natriuretic Peptide Level in Patients with Type 2 Diabetes

et al. 2005

View full text Add to dashboard Cite

show abstract

“…In patients with heart failure, deceased clearance from the kidneys contributes to the elevated BNP level [17]. Among patients with type 1 diabetes mellitus, BNP infusion increased urine excretion of albumin [18]. Low clearance of BNP might therefore increase urine excretion of albumin.…”

Section: Discussionmentioning

confidence: 99%

B-type natriuretic peptide and renal function in Japanese patients with type 2 diabetes mellitus: The Dogo Study

et al. 2017

View full text Add to dashboard Cite

THE LEADING CAUSE OF THE DEATH among patients with renal dysfunction is cardiovascular diseases [1], and the importance of the interaction between the heart and kidneys is widely note [2]. Plasma B-type natriuretic peptide (BNP) releases from the ventricles in response to hemodynamic stress, and BNP is one of the predictive markers for cardiovascular events [3,4].Among patients with type 2 diabetes mellitus, sev- Abstract. Among patients with type 2 diabetes mellitus, the association between B-type natriuretic peptide (BNP) and renal function remains controversial. We therefore investigated this issue among Japanese patients with type 2 diabetes mellitus. This study included 687 Japanese patients with type 2 diabetes mellitus. BNP levels were divided at quartile points on the basis of the distribution. We used four outcomes regarding the renal function: 1) chronic kidney disease (CKD): estimated glomerular filtration rate (eGFR) < 60mL/min/1.72m 2 , 2) advanced CKD: eGFR < 30mL/min/1.72m 2 , 3) microalbuminuria: urinary albumin creatinine ratio (UACR) ≥ 30 mg/g creatinine, and 4) macroalbuminuria: UACR ≥ 300 mg/g creatinine. The prevalence values of CKD, advanced CKD, microalbuminuria, and macroalbuminuria were 27.4, 2.5%, 31.4%, and 9.3%, respectively. Highest BNP (≥ 39.2 ng/mL) was independently positively associated with microalbuminuria and macroalbuminuria (adjusted ORs, 2.61 [95% CI: 1.53-4.49] and 3.45 [95% CI: 1.46-8.72], respectively). High BNP was not associated with advanced CKD or CKD. There was a statistically significant positive exposure-response relationships between the BNP level and advanced CKD, microalbuminuria, and macroalbuminuria (p for trend = 0.047, 0.001, and 0.003, respectively). BNP level may be independently positively associated with advanced CKD, microalbuminuria, and macroalbuminuria but not CKD in Japanese patients with type 2 diabetes mellitus.

show abstract

“…One clamp study has shown that BNP infusion increases urine albumin excretion in patients with type I diabetes. 26 It was reported that this may be due to a downregulation of A-type guanylate cyclasecoupled natriuretic peptide receptors in renal tubules or due to elevated NT proBNP levels leading to higher glomerular hydraulic pressure or higher capillary permeability and possibly increased albumin excretion. 27 Zietse et al and McKenna et al 26,28 have shown that during ANP infusion, albumin excretion increases in diabetic patients and suggested that ANP increases the transcapillary escape rate of albumin.…”

Section: Discussionmentioning

confidence: 99%

“…26 It was reported that this may be due to a downregulation of A-type guanylate cyclasecoupled natriuretic peptide receptors in renal tubules or due to elevated NT proBNP levels leading to higher glomerular hydraulic pressure or higher capillary permeability and possibly increased albumin excretion. 27 Zietse et al and McKenna et al 26,28 have shown that during ANP infusion, albumin excretion increases in diabetic patients and suggested that ANP increases the transcapillary escape rate of albumin. Because both ANP and BNP bind to the same receptor and have the same biological activity, it is conceivable that abnormally elevated levels of BNP also cause increased glomerular hydraulic pressure and thus induce increased albumin excretion in diabetic patients.…”

Section: Discussionmentioning

confidence: 99%

NGAL and NT-proBNP levels in diabetic patients with macroproteinuria

Taşkapan¹,

Taşkapan²,

Orman³

et al. 2013

Renal Failure

View full text Add to dashboard Cite

Brain natriuretic peptide increases urinary albumin and alpha‐1 microglobulin excretion in Type 1 diabetes mellitus

Abstract: Intravenous infusion of BNP and ANP both increase the urine excretion of albumin and the tubular protein alpha1 microglobulin, independent of creatinine clearance.

Cited by 17 publications

References 49 publications

Characterization of Plasma Brain Natriuretic Peptide Level in Patients with Type 2 Diabetes

Characterization of Plasma Brain Natriuretic Peptide Level in Patients with Type 2 Diabetes

B-type natriuretic peptide and renal function in Japanese patients with type 2 diabetes mellitus: The Dogo Study

NGAL and NT-proBNP levels in diabetic patients with macroproteinuria

Contact Info

Product

Resources

About